Pulse Biosciences (PLSE) announced the first successful procedures in a multicenter IRB-approved study using Pulse Biosciences’ nsPFA Percutaneous Electrode System for the treatment of benign thyroid nodules.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE:
- Pulse Biosciences’ Earnings Call: Clinical Gains and Financial Hurdles
- Pulse Biosciences Publishes Promising Thyroid Study Results
- Pulse Biosciences publishes benign thyroid nodules data in Journal Thyroid
- Pulse Biosciences Reports Q2 2025 Progress and Results
- Pulse Biosciences Appoints New VP of Accounting